Aerobic exercise holds promise for treating cognitive impairment and altering brain atrophy in Alzheimer's disease (AD). AD currently afflicts 5.4 million Americans and will affect 14 million by 2050 if no cure is found. Cognitive impairment is the hallmark symptom of AD and contributes to the manifestation of other symptoms that result in poor outcomes, including low quality of life, early institutionalization, and high costs (valuedat $202.6 billion in 2010). Exercise studies in AD are just emerging and have produced conflicting findings on cognitive outcomes, largely due to low doses, poor delivery of aerobic exercise, and lack of controls. This pilot randomized controlled trial (RCT) will be the first to investigate the effects of a novel 6-month, individualized, moderate-intensity cycling intervention on cognition and hippocampal volume in community-dwelling older adults with mild-to-moderate AD. Two complementary frameworks guide our study: the cardiovascular fitness hypothesis that suggests increased aerobic fitness improves cognition;and the biological mechanistic theory which addresses the lack of specificity of the first framework by identifying the mechanisms of action of aerobic exercise. Dr. Yu (PI), an Early-Stage Investigator, has successfully led her interdisciplinary team to develop and execute the 6-month cycling intervention, establish the feasibility of recruitment, retention, and adherence, and show positive cognitive results via 3 pretest posttest studies. This pilot RCT will randomize 90 subjects to the 6-month cycling intervention or attention control (sham exercise) groups using permuted blocks of 3 and 6 subjects randomly and a 2:1 allocation ratio, and follow them for another 6 months. Cognition will be measured by the AD Assessment Scale-Cognition (ADAS-Cog) at baseline, 3, 6, 9, and 12 months. Hippocampal volume will be measured by magnetic resonance imaging (MRI) at baseline, 6, and 12 months. The sample size will give us 80% power to detect at least a 2.5-point difference in within-group changes in ADAS-Cog at 6 months.
The specific aims are:
Aim I. Determine the immediate effect of the cycling intervention on cognition in AD. We hypothesize that intervention subjects will have a smaller within-group increase in ADAS-Cog at 6 months than placebo subjects in AD drug RCTs, while control subjects will have the same increase as placebo subjects in AD drug RCTs.
Aim II. Examine if the cycling intervention slows cognitive decline in AD from baseline to 12 months. We expect that intervention subjects will show a smaller increase in ADAS-Cog over 12 months than control subjects.
Aim III : Assess the effect of aerobic exercise on hippocampal volume in AD over 12 months using MRI. We expect that intervention subjects will have a smaller decrease in hippocampal volume over 12 months than control subjects. The study's broad impacts are to address the critical gap in knowledge of the therapeutic effects of aerobic exercise in AD and offer a potentially effective treatment for AD. This pilot study will inform a future full-scale RCT that will address our long-term goal of elucidating how aerobic exercise alters AD progression and provide important foundations for future research.
The proposed study will determine if 6-month aerobic exercise will affect the decline in cognition and hippocampal volume in older adults with mild-to-moderate Alzheimer's disease (AD). This study could potentially reduce the public health impact of AD by providing an effective treatment, delaying nursing-home placement, increasing physical function, improving quality of life, and curbing the prohibitive health care costs for the growing population with AD and their 15 million family caregivers. This study could further help both the health care providers and the public to engage older adults with AD in aerobic exercise and address issues to advance future research.
|Yu, Fang; Vock, David M; Barclay, Terry R (2018) Executive function: Responses to aerobic exercise in Alzheimer's disease. Geriatr Nurs 39:219-224|
|Li, Danni; Huang, Fangying; Zhao, Yingchun et al. (2018) Plasma lipoproteome in Alzheimer's disease: a proof-of-concept study. Clin Proteomics 15:31|
|Ramanan, Vijay K; Przybelski, Scott A; Graff-Radford, Jonathan et al. (2018) Statins and Brain Health: Alzheimer's Disease and Cerebrovascular Disease Biomarkers in Older Adults. J Alzheimers Dis 65:1345-1352|
|Mielke, Michelle M; Hagen, Clinton E; Xu, Jing et al. (2018) Plasma phospho-tau181 increases with Alzheimer's disease clinical severity and is associated with tau- and amyloid-positron emission tomography. Alzheimers Dement 14:989-997|
|Li, Danni; Misialek, Jeffrey R; Huang, Fangying et al. (2018) Independent Association of Plasma Hydroxysphingomyelins With Physical Function in the Atherosclerosis Risk in Communities (ARIC) Study. J Gerontol A Biol Sci Med Sci 73:1103-1110|
|Shah, Krupa N; Lin, Feng V; Yu, Fang et al. (2017) Activity engagement and physical function in old age sample. Arch Gerontol Geriatr 69:55-60|
|Zhang, Rui; Simon, Gyorgy; Yu, Fang (2017) Advancing Alzheimer's research: A review of big data promises. Int J Med Inform 106:48-56|
|Weiner, Michael W; Harvey, Danielle; Hayes, Jacqueline et al. (2017) Effects of traumatic brain injury and posttraumatic stress disorder on development of Alzheimer's disease in Vietnam Veterans using the Alzheimer's Disease Neuroimaging Initiative: Preliminary Report. Alzheimers Dement (N Y) 3:177-188|
|Ahn, Sangwoo; Chen, Yan; Bredow, Tim et al. (2017) Effects of Non-Pharmacological Treatments on Quality of Life in Parkinson's Disease: A Review. J Parkinsons Dis Alzheimers Dis 4:|
|Zeydan, Burcu; Deelchand, Dinesh K; Tosakulwong, Nirubol et al. (2017) Decreased Glutamate Levels in Patients with Amnestic Mild Cognitive Impairment: An sLASER Proton MR Spectroscopy and PiB-PET Study. J Neuroimaging 27:630-636|
Showing the most recent 10 out of 29 publications